Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SYNVIA

Financiado

Cerrado

Synthetic viability of homologous recombination deficient cancers

Although various effective anti-cancer drug treatments have become available over the last decades, drug resistance remains the major cause of death of cancer patients. Striking examples are patients with tumors that are defective... ver más

30/06/2021

UNIVERSITAET BERN

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UNIVERSITAET BERN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-06-30

ERC-CoG-2015: ERC Consolidator Grant

I+D

Cerrada hace 9 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UNIVERSITAET BERN

2.00M€ | Lider

DOW CHEMICAL IBERICA

2.14M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SYNTRAIN Targeting SYNthetic lethal interactions for new cancer treat... 4M€ Cerrado

SYNTHLE BRCA Synthetic lethality approaches to BRCA associated cancer 169K€ Cerrado

TargetBRCA To develop a new targeted therapy for the treatment of naive... 150K€ Cerrado

DDR SYNVIA Cellular models for human disease alleviation mechanisms a... 300K€ Cerrado

GENECADD GEnetic NEtworks as a tool for anti CAncer Drug Development 3M€ Cerrado

SYNvia Exploring synthetic lethality and synthetic viability to... 238K€ Cerrado

Duración del proyecto: 62 meses Fecha Inicio: 2016-04-13
Fecha Fin: 2021-06-30

Líder del proyecto

UNIVERSITAET BERN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Although various effective anti-cancer drug treatments have become available over the last decades, drug resistance remains the major cause of death of cancer patients. Striking examples are patients with tumors that are defective in DNA repair by homologous recombination (HR). Despite initial responses to cancer therapy, resistance of primary or disseminated tumors eventually emerges, which minimizes therapeutic options and greatly reduces survival. The molecular mechanisms underlying this therapy escape are often poorly understood. In the SYNVIA project I will address the problem of therapy escape by using powerful genetically engineered mouse models for BRCA1- and BRCA2-deficient breast cancer, which closely mimic the human disease. Due to the BRCA inactivation, the tumors that arise lack HR-directed DNA repair. Similar to the situation in cancer patients, we observe that cancer cells in these models eventually escape the deadly effects of chemotherapy or novel targeted drugs. Thus, these resistance models provide a unique opportunity to explore therapy escape mechanisms. I propose an approach that will take the in vivo analysis of therapy resistance mechanisms to a new level. By synergizing the advantages of next generation sequencing with functional genetic screens in tractable model systems, I will explore novel mechanisms that cause resistance of HR-deficient cancers by the loss of another gene (synthetic viability). I provide evidence that new mechanisms of resistance can be identified with this approach. In an innovative step, I will generate genome-wide alterations using the revolutionizing CRISPR/Cas technology. Mutations will also be introduced into 3D tumor organoid cultures, as we found that these are more physiologically relevant. I am convinced that the combination of these state-of-the-art approaches will yield highly useful information for designing effective approaches to circumvent or reverse therapy escape in human cancer patients.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores